For pharmaceuticals manufacturers, progressing digitalisation and moving to the cloud has been notoriously slow, and misperceptions of what moving to the cloud entails have been a significant factor in this lack of adoption.
Manufacturers with established legacy systems are often unduly concerned about the security aspects of moving to cloud. They have also been hesitant to invest in new infrastructure, even though the long-term savings offered by cloud platforms outweigh its short-term costs.
Despite this lag, the move from on-premise, local software installation, to cloud has become more commonplace. Many manufacturers have taken an intermediate hybrid cloud approach, which refers to a mixed computing, storage, and services environment made up of on-premises infrastructure, private cloud services and a public cloud.